Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
China
The First Affiliated Hospital of Nanchang University, Nanchang The Haematology Hospital of the Chinese Academy of Medical Sciences, Tianjin Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan